Patents by Inventor Werner Kramer

Werner Kramer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220213675
    Abstract: A toilet device with inspection functions, highly controllable cleaning, drying, visual observation and reporting functions. Certain embodiments of such observation, inspection, cleaning and drying of the user's posterior and genitals are introduced in some detail, and so are the automatic self-cleaning and drying mechanisms, structures and methods of the observation and cleaning devices. This device allows the user to take full control of observing their bowel movement as well as controlling proper cleaning and drying afterwards. In addition, toilet device embodiments are presented which can be combined with the described observation and cleaning features and which support people lacking mobility, strength or coordination or having sensory impairments by executing certain bodily motions, such as bringing the user into a more or less crouching or rocking position in order to facilitate bowel movement. For all actuations, activation via voice, push button, touch screen or joystick control are all envisioned.
    Type: Application
    Filed: May 14, 2020
    Publication date: July 7, 2022
    Inventors: Karl-Josef Kramer, Werner Kramer
  • Patent number: 8106023
    Abstract: This invention relates to Novel 1,4-benzothiepin-1,1-dioxide derivatives with improved properties, method for producing the same, drugs containing said compounds and use thereof.
    Type: Grant
    Filed: May 14, 2009
    Date of Patent: January 31, 2012
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Heiner Glombik, Wendelin Frick, Stefan Theis, Hubert Heuer, Hans-Ludwig Schaefer, Werner Kramer
  • Patent number: 8101583
    Abstract: This invention relates to Novel 1,4-benzothiepin-1,1-dioxide derivatives which are substituted with fluorine, method for producing the same, drugs containing said compounds and use thereof.
    Type: Grant
    Filed: May 14, 2009
    Date of Patent: January 24, 2012
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Heiner Glombik, Wendelin Frick, Stefan Theis, Hubert Heuer, Hans-Ludwig Schaefer, Werner Kramer
  • Patent number: 7956085
    Abstract: This invention relates to Novel 1,4-benzothiepine 1,1-dioxide derivatives substituted by benzyl radicals, method for their preparation, pharmaceuticals comprising these compounds, and the use thereof.
    Type: Grant
    Filed: May 14, 2009
    Date of Patent: June 7, 2011
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Wendelin Frick, Heiner Glombik, Stefan Theis, Hubert Heuer, Hans-Ludwig Schaefer, Werner Kramer
  • Patent number: 7923468
    Abstract: This invention relates to Novel 1,4-benzothiepin-1,1-dioxide derivatives which are substituted with cyclohexyl groups, method for producing the same, drugs containing said compounds and use thereof.
    Type: Grant
    Filed: May 14, 2009
    Date of Patent: April 12, 2011
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Wendelin Frick, Heiner Glombik, Stefan Theis, Hubert Heuer, Hans-Ludwig Schaefer, Werner Kramer
  • Publication number: 20100261664
    Abstract: Novel heterocyclic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof The invention relates to substituted heterocyclic fluoroglycoside derivatives of the formula I in which the radicals have the stated meanings, and their physiologically tolerated salts and processes for their preparation. The compounds are suitable for example as antidiabetics.
    Type: Application
    Filed: May 25, 2010
    Publication date: October 14, 2010
    Applicant: SANOFI-AVENTIS DEUTSCHLAND GMBH
    Inventors: Wendelin FRICK, Heiner GLOMBIK, Werner KRAMER, Hubert HEUER, Harm BRUMMERHOP, Oliver PLETTENBURG
  • Patent number: 7786103
    Abstract: The invention describes a method for isolating an intestinal protein which is able to bind cholesterol and/or cholesterol uptake inhibitors.
    Type: Grant
    Filed: October 16, 2007
    Date of Patent: August 31, 2010
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Werner Kramer, Wendelin Frick
  • Patent number: 7772429
    Abstract: The invention relates to the compound of the formula 1 and to its physiologically acceptable salts. The compound is suitable, for example, as a hypolipidemic.
    Type: Grant
    Filed: March 26, 2007
    Date of Patent: August 10, 2010
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Gerhard Jaehne, Wendelin Frick, Andreas Lindenschmidt, Stefanie Flohr, Hubert Heuer, Hans-Ludwig Schaefer, Werner Kramer, Eric Galia, Heiner Glombik
  • Publication number: 20100160282
    Abstract: Compounds of the formula I, in which R1, R2, R3, R4, R5, and R6 have the meanings given in the description, and their physiologically acceptable salts. The compounds are suitable for use, for example, as hypolipidemics.
    Type: Application
    Filed: December 23, 2009
    Publication date: June 24, 2010
    Applicant: SANOFI-AVENTIS DEUTSCHLAND GMBH
    Inventors: Heiner Glombik, Werner Kramer, Stefanie Flohr, Wendelin Frick, Hubert Heuer, Gerhard Jaehne, Andreas Lindenschmidt, Hans-Ludwig Schäfer
  • Publication number: 20100062991
    Abstract: This invention relates to Novel 1,4-benzothiepin-1,1-dioxide derivatives which are substituted with fluorine, method for producing the same, drugs containing said compounds and use thereof.
    Type: Application
    Filed: May 14, 2009
    Publication date: March 11, 2010
    Applicant: SANOFI-AVENTIS DEUTUSCHLAND GMBH
    Inventors: Heiner Glombik, Wendelin Frick, Stefan Theis, Hubert Heuer, Hans-Ludwig Schaefer, Werner Kramer
  • Patent number: 7674773
    Abstract: Compounds of the formula I, in which R1, R2, R3, R4, R5, and R6 have the meanings given in the description, and their physiologically acceptable salts. The compounds are suitable for use, for example, as hypolipidemics.
    Type: Grant
    Filed: June 17, 2005
    Date of Patent: March 9, 2010
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Heiner Glombik, Werner Kramer, Stefanie Flohr, Wendelin Frick, Hubert Heuer, Gerhard Jaehne, Andreas Lindenschmidt, Hans-Ludwig Schäfer
  • Patent number: 7671047
    Abstract: One embodiment of the invention relates to compounds of the formula I, in which R1, R2, R3, R4, R5 and R6 have the meanings given in the specification. Other embodiments of the invention relate to physiologically acceptable salts of the compounds of formula I, to processes for their preparation and to medicaments comprising these compounds. The compounds of the invention are suitable for use, for example, as hypolipidemics.
    Type: Grant
    Filed: June 18, 2003
    Date of Patent: March 2, 2010
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Gerhard Jaehne, Wendelin Frick, Stefanie Flohr, Andreas Lindenschmidt, Heiner Glombik, Werner Kramer, Hubert Heuer, Hans-Ludwig Schaefer
  • Patent number: 7666848
    Abstract: Novel thiophene glycoside derivatives of the formula I in which the radicals have the stated meanings, and the physiologically tolerated salts thereof and processes for their preparation are disclosed. The compounds are suitable, for example, as antidiabetics.
    Type: Grant
    Filed: August 14, 2006
    Date of Patent: February 23, 2010
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Heiner Glombik, Wendelin Frick, Hubert Heuer, Werner Kramer, Harm Brummerhop, Oliver Plettenburg
  • Publication number: 20100035962
    Abstract: This Invention relates to Novel 1,4-benzothiepin-1,1-dioxide derivatives which are substituted with cyclohexyl groups, method for producing the same, drugs containing said compounds and use thereof.
    Type: Application
    Filed: May 14, 2009
    Publication date: February 11, 2010
    Applicant: SANOFI-AVENTIS DEUTSCHLAND GMBH
    Inventors: Wendelin Frick, Heiner Glombik, Stefan Theis, Hubert Heuer, Hans-Ludwig Schaefer, Werner Kramer
  • Publication number: 20100035834
    Abstract: This invention relates to Novel 1,4-benzothiepin-1,1-dioxide derivatives with improved properties, method for producing the same, drugs containing said compounds and use thereof.
    Type: Application
    Filed: May 14, 2009
    Publication date: February 11, 2010
    Applicant: SANOFI-AVENTIS DEUTUSCHLAND GMBH
    Inventors: Heiner Glombik, Wendelin Frick, Stefan Theis, Hubert Heuer, Hans-Ludwig Schaefer, Werner Kramer
  • Publication number: 20100035961
    Abstract: This invention relates to Novel 1,4-benzothiepine 1,1-dioxide derivatives substituted by benzyl radicals, method for their preparation, pharmaceuticals comprising these compounds, and the use thereof.
    Type: Application
    Filed: May 14, 2009
    Publication date: February 11, 2010
    Applicant: SANOFI-AVENTIS DEUTSCHLAND GMBH
    Inventors: Wendelin Frick, Heiner Glombik, Stefan Theis, Hubert Heuer, Hans-Ludwig Schaefer, Werner Kramer
  • Publication number: 20090264402
    Abstract: The invention therefore relates to the compound of the formula I or a pharmaceutically acceptable salt thereof, its pharmaceutically composition and uses.
    Type: Application
    Filed: April 30, 2009
    Publication date: October 22, 2009
    Applicant: SANOFI-AVENTIS DEUTSCHLAND GMBH
    Inventors: Gerhard Jaehne, Wendelin Frick, Andreas Lindenschmidt, Hubert Heuer, Hans-Ludwig Schaefer, Werner Kramer, Claus-Dieter Graf, Wolfgang Schmider
  • Patent number: 7579339
    Abstract: One embodiment of the invention relates to compounds of the formula I, in which R1, R2, R3, R4, R5 and R6 have the meanings given in the specification. Other embodiments of the invention relate to physiologically acceptable salts of compounds of formula I, to processes for their preparation and to medicaments comprising these compounds. The compounds of the invention are suitable for use, for example, as hypolipidemics.
    Type: Grant
    Filed: August 10, 2006
    Date of Patent: August 25, 2009
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Gerhard Jaehne, Wendelin Frick, Stefanie Flohr, Andreas Lindenschmidt, Heiner Glombik, Werner Kramer, Hubert Heuer, Hans-Ludwig Schaefer
  • Publication number: 20090143473
    Abstract: Use of inhibitors of the cellular Na+/H+ exchanger (NHE) for the production of a medicament for the normalization of serum lipids. The active compounds identified as inhibitors of the cellular Na+/H+ exchanger (NHE) are used for the production of a medicament for the normalization of serum lipids. They are used for the production of a medicament for lowering the blood lipid level and illnesses caused thereby, as well as the endothelial dysfunction syndrome and illness caused thereby.
    Type: Application
    Filed: February 3, 2009
    Publication date: June 4, 2009
    Applicant: SANOFI-AVENTIS DEUTSCHLAND GMBH
    Inventors: Hans Jochen LANG, Hans-Willi JANSEN, Jan-Robert SCHWARK, Heinz-Werner KLEEMANN, Oliver JUNG, Hans-Ludwig SCHAFER, Wolfgang LINZ, Werner KRAMER, Bernward SCHOLKENS, Eugen FALK
  • Publication number: 20080274947
    Abstract: The present invention comprises compounds and compositions for the treatment of metabolic disorders and more particularly, those insulin-related metabolic disorders of the blood such as hyperlipidemia, diabetes, insulin-resistance and the like comprising diphenylazetidinones compounds which have an additional hydroxy function in the 2? position and their salts. The invention therefore relates to compounds of formula I: in which the meanings R1, R2, R3, R4, R5, R6 are defined herein.
    Type: Application
    Filed: May 19, 2008
    Publication date: November 6, 2008
    Applicant: SANOFI-AVENTIS DEUTSCHLAND GMBH
    Inventors: Gerhard JAEHNE, Wendelin FRICK, Andreas LINDENSCHMIDT, Hubert HEUER, Hans-Ludwig SCHAEFER, Werner KRAMER, Wolfgang SCHMIDER